---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009462"
form_type: "8-K"
ticker: "SIGY"
cik: "0001642159"
company_name: "Sigyn Therapeutics, Inc."
filed_at: "2025-03-07T23:59:59+00:00"
generated_at: "2026-05-25T03:44:54.116231+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sigyn Therapeutics CFO Gerald DeCiccio Retires; CEO James Joyce Appointed Interim CFO

## Summary
- CFO Gerald DeCiccio retired effective February 26, 2025, with no disagreement with the company.
- CEO James Joyce will serve as interim CFO following DeCiccio's retirement.
- Sigyn entered into a Consulting Agreement with DeCiccio for continued financial support services.
- CEO released a letter on March 5, 2025, outlining Sigyn Therapy's potential against emerging viral threats.
- Sigyn Therapy targets viruses, bacterial toxins, inflammatory cytokines, and has a clinical strategy for ESRD patients.

## SEC filing metadata
- accession: 0001493152-25-009462
- form_type: 8-K
- ticker: SIGY
- cik: 0001642159
- company_name: Sigyn Therapeutics, Inc.
- filed_at: 2025-03-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642159/000149315225009462/0001493152-25-009462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642159/000149315225009462/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009462
- JSON: https://secwatch.observer/filing/0001493152-25-009462.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009462.txt

## Key facts
- Executive change
  James Joyce was appointed as interim Chief Financial Officer at Sigyn Therapeutics, Inc..
  - Action: appointed
  - Role: interim Chief Financial Officer
  source text: Mr. James Joyce, our Chief Executive Officer, will serve as our interim Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642159/000149315225009462/0001493152-25-009462-index.htm
- Executive change
  Gerald DeCiccio retired as Chief Financial Officer at Sigyn Therapeutics, Inc..
  - Action: retired
  - Role: Chief Financial Officer
  source text: On February 26, 2025, our Chief Financial Officer, Mr. Gerald DeCiccio provided us a notice of retirement, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642159/000149315225009462/0001493152-25-009462-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.